No More Injections? FDA Clears First Daily Pill for Moderate to Severe Psoriasis
For millions of people living with moderate-to-severe plaque psoriasis, the "gold standard" of treatment has long come with a literal sting: regular injections of biologic medications. While these shots are highly effective at clearing skin, many patients suffer from "injection fatigue" or a simple dislike of needles.
That landscape changed forever after the FDA (Food and Drug Administration) approved Icotrokinra, a once-daily pill that brings the power of an injectable biologic into the palm of your hand. The FDA authorized Icotrokinra for adults and adolescents 12 years and older weighing at least 40 kg.
A "Biologic in a Pill"
Icotrokinra is a first-of-its-kind treatment known as a targeted oral peptide. While traditional pills often affect several parts of the immune system, Icotrokinra is designed with extreme precision. It works by blocking the interleukin-23 (IL-23) receptor, which acts as a major "master switch" for the inflammation that causes red, scaly psoriasis plaques.
Until now, only injectable medicines could target this specific pathway so accurately. Experts are calling this a "game-changer" because it offers "biologic-like" efficacy without the need for a syringe.
What the Results Show
The FDA's decision was based on a massive research program involving 2,500 patients. The results were striking:
- Clear Skin: Approximately 70 percent of patients achieved clear or almost clear skin within just 16 weeks.
- Near-Total Clearance: More than half (55 percent) of patients saw a 90 percent or greater improvement in their symptoms.
- Hard-to-Treat Areas: The pill was particularly effective at clearing psoriasis in difficult spots like the scalp and genitals.
In head-to-head trials, Icotrokinra even outperformed existing oral treatments, showing significantly higher rates of skin clearance than older daily pills.
Safety and Ease of Use
One great thing about Icotrokinra is that it’s highly safe. In tests, people taking it had about the same side effects as those taking a fake pill. The most common side effects were mild, like headaches, feeling a little sick, a small cough, fungal infections, and fatigue.
Taking the medication is straightforward: you take one pill when you wake up on an empty stomach with water, then wait 30 minutes before eating. Because it targets the immune system, doctors will screen patients for tuberculosis (TB) before starting the treatment.
A Growing Family of Oral Options
Icotrokinra joins another innovative pill, Deucravacitinib, which was first approved for skin in 2022 and recently received a new FDA approval to treat psoriatic arthritis. This means patients now have multiple oral choices depending on whether they need to clear their skin, treat their joints, or both.
Better Access and Lower Costs
High-tech medicines can cost a lot, but 2026 brings some good news. The approval of Icotrokinra marks a pivotal moment. For the first time, patients don't have to choose between the convenience of a pill and the high performance of a biologic. If you’ve been cycling through creams or are tired of injections, it may be time to talk to your dermatologist about this new once-daily option.
